UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands

Verhoef, T; Redekop, WK; de Boer, A; Maitland-van der Zee, AH; (2015) Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. Pharmacogenomics , 16 (2) pp. 101-114. 10.2217/pgs.14.149.. Green open access

[thumbnail of Verhoef_Supplement.pdf]
Preview
Text
Verhoef_Supplement.pdf

Download (183kB) | Preview
[thumbnail of Verhoef_Tables_clean version.pdf]
Preview
Text
Verhoef_Tables_clean version.pdf

Download (281kB) | Preview
[thumbnail of Verhoef_Figures_clean version.pdf]
Preview
Text
Verhoef_Figures_clean version.pdf

Download (721kB) | Preview
[thumbnail of Verhoef_Economic evaluation of a pharmacogenetic dosing algorithm_clean version.pdf]
Preview
Text
Verhoef_Economic evaluation of a pharmacogenetic dosing algorithm_clean version.pdf

Download (167kB) | Preview

Abstract

Aims: to investigate the cost-effectiveness of a pharmacogenetic dosing algorithm versus a clinical dosing algorithm for coumarin anticoagulants in The Netherlands. Materials & methods: A decision-analytic Markov model was used to analyze the cost-effectiveness of pharmacogenetic dosing of phenprocoumon and acenocoumarol versus clinical dosing. Results: Pharmacogenetic dosing increased costs by €33 and QALYs by 0.001. The incremental cost-effectiveness ratios (ICERs) were €28,349 and €24,427 per QALY gained for phenprocoumon and acenocoumarol respectively. At a willingness to pay threshold of €20,000 per QALY, the pharmacogenetic dosing algorithm was not likely to be cost-effective compared to the clinical dosing algorithm. Conclusions: Pharmacogenetic dosing improves health only slightly when compared with clinical dosing. However, availability of low-cost genotyping would make it a cost-effective option.

Type: Article
Title: Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.2217/pgs.14.149.
Publisher version: http://dx.doi.org/10.2217/pgs.14.149.
Language: English
Additional information: © 2015 Future Medicine Ltd
Keywords: acenocoumarol, atrial fibrillation, health economics, pharmacogenetics, phenprocoumon
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Epidemiology and Health > Applied Health Research
URI: https://discovery.ucl.ac.uk/id/eprint/1460052
Downloads since deposit
342Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item